Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

NCT01209143 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01209143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01209143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2010
Completion date
March 31, 2012
Enrollment
52 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid cancers